GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (NAS:GRFS) » Definitions » EV-to-EBITDA

GRFS (Grifols) EV-to-EBITDA : 23.26 (As of Oct. 31, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Grifols EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Grifols's enterprise value is $17,951 Mil. Grifols's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was $772 Mil. Therefore, Grifols's EV-to-EBITDA for today is 23.26.

The historical rank and industry rank for Grifols's EV-to-EBITDA or its related term are showing as below:

GRFS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.96   Med: 17.2   Max: 32.89
Current: 23.21

During the past 13 years, the highest EV-to-EBITDA of Grifols was 32.89. The lowest was 6.96. And the median was 17.20.

GRFS's EV-to-EBITDA is ranked worse than
65.12% of 711 companies
in the Drug Manufacturers industry
Industry Median: 14.78 vs GRFS: 23.21

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-10-31), Grifols's stock price is $8.71. Grifols's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $0.206. Therefore, Grifols's PE Ratio (TTM) for today is 42.28.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Grifols EV-to-EBITDA Historical Data

The historical data trend for Grifols's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols EV-to-EBITDA Chart

Grifols Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.50 17.06 21.07 15.49 18.71

Grifols Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.49 34.74 33.02 18.71 22.95

Competitive Comparison of Grifols's EV-to-EBITDA

For the Drug Manufacturers - General subindustry, Grifols's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grifols's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grifols's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Grifols's EV-to-EBITDA falls into.



Grifols EV-to-EBITDA Calculation

Grifols's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=17950.835/771.621
=23.26

Grifols's current Enterprise Value is $17,951 Mil.
Grifols's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $772 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Grifols  (NAS:GRFS) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Grifols's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=8.71/0.206
=42.28

Grifols's share price for today is $8.71.
Grifols's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.206.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Grifols EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Grifols's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Grifols Business Description

Address
Avinguda de la Generalitat, 152, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.